BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ahmed Mohammed HF, Roberts LR. Should AFP (or any biomarkers) be used for HCC surveillance? Curr Hepatol Rep 2017;16:137-45. [PMID: 29085770 DOI: 10.1007/s11901-017-0349-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Chen J, Cao J, Wang P, He X. NT5DC2 is a novel prognostic marker in human hepatocellular carcinoma. Oncol Lett 2020;20:70. [PMID: 32863903 DOI: 10.3892/ol.2020.11931] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Xing H, Qiu H, Ding X, Han J, Li Z, Wu H, Yan C, Li H, Han R, Zhang H, Li C, Wang M, Wu M, Shen F, Zheng Y, Yang T. Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma. Biomark Med 2019;13:545-55. [PMID: 31140827 DOI: 10.2217/bmm-2018-0414] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
3 Rau KM, Liu CT, Hsiao YC, Hsiao KY, Wang TM, Hung WS, Su YL, Liu WC, Wang CH, Hsu HL, Chuang PH, Cheng JC, Tseng CP. Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response. J Clin Med. 2020;9. [PMID: 32071283 DOI: 10.3390/jcm9010188] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
4 Feng L, Wang Y, Wang X, An S, Aizimuaji Z, Tao C, Zhang K, Cheng S, Wu J, Xiao T, Rong W. Integrated analysis of the rhesus monkey liver transcriptome during development and human primary HCC AFP-related gene expression. Mol Ther Nucleic Acids 2021;25:406-15. [PMID: 34484865 DOI: 10.1016/j.omtn.2021.06.004] [Reference Citation Analysis]
5 Zheng L, Li H, Huang J, Shin J, Luo S, Guo C, Zhao Y, Li F. Serum midkine levels for the diagnosis and assessment of response to interventional therapy in patients with hepatocellular carcinoma. J Interv Med 2021;4:39-45. [PMID: 34805946 DOI: 10.1016/j.jimed.2020.10.009] [Reference Citation Analysis]
6 Mocan T, Simão AL, Castro RE, Rodrigues CMP, Słomka A, Wang B, Strassburg C, Wöhler A, Willms AG, Kornek M. Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning? J Clin Med 2020;9:E1541. [PMID: 32443747 DOI: 10.3390/jcm9051541] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
7 Chan HLY, Vogel A, Berg T, De Toni EN, Kudo M, Trojan J, Eiblmaier A, Klein H, Hegel JK, Sharma A, Madin K, Rolny V, Lisy M, Piratvisuth T. Performance evaluation of the Elecsys PIVKA‐II and Elecsys AFP assays for hepatocellular carcinoma diagnosis. JGH Open. [DOI: 10.1002/jgh3.12720] [Reference Citation Analysis]
8 Westin J, Aleman S, Castedal M, Duberg A, Eilard A, Fischler B, Kampmann C, Lindahl K, Lindh M, Norkrans G, Stenmark S, Weiland O, Wejstål R. Management of hepatitis B virus infection, updated Swedish guidelines. Infectious Diseases 2020;52:1-22. [DOI: 10.1080/23744235.2019.1675903] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
9 Xun R, Lu H, Wang X. Identification of CDC25C as a Potential Biomarker in Hepatocellular Carcinoma Using Bioinformatics Analysis. Technol Cancer Res Treat 2020;19:1533033820967474. [PMID: 33111630 DOI: 10.1177/1533033820967474] [Reference Citation Analysis]
10 Mücke VT, Thomas D, Mücke MM, Waidmann O, Zeuzem S, Sarrazin C, Pfeilschifter J, Vermehren J, Finkelmeier F, Grammatikos G. Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response. Liver Int 2019;39:2174-83. [PMID: 31207039 DOI: 10.1111/liv.14178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
11 Zhang Q, Han Z, Tao J, Zhao M, Zhang W, Li P, Tang L, Gu Y. An innovative peptide with high affinity to GPC3 for hepatocellular carcinoma diagnosis. Biomater Sci 2018;7:159-67. [PMID: 30417190 DOI: 10.1039/c8bm01016a] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
12 Wu H, Wang MD, Liang L, Xing H, Zhang CW, Shen F, Huang DS, Yang T. Nanotechnology for Hepatocellular Carcinoma: From Surveillance, Diagnosis to Management. Small 2021;17:e2005236. [PMID: 33448111 DOI: 10.1002/smll.202005236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
13 El-Nakeep S. Molecular and genetic markers in hepatocellular carcinoma: In silico analysis to clinical validation (current limitations and future promises). World J Gastrointest Pathophysiol 2022; 13(1): 1-14 [PMID: 35116176 DOI: 10.4291/wjgp.v13.i1.1] [Reference Citation Analysis]
14 Lee YS, Ko E, Yoon EL, Jung YK, Kim JH, Seo YS, Yim HJ, Kim KH, Kwon SY, Yeon JE, Um SH, Byun KS. Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP. J Clin Med 2020;9:E323. [PMID: 31979338 DOI: 10.3390/jcm9020323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Liu M, Huang L, Wu J, Zhang H, Ai W, Zhang R. Possible roles of Golgi protein-73 in liver diseases. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100720] [Reference Citation Analysis]
16 Kim TH, Woo S, Han S, Suh CH, Do RKG, Lee JM. Risk Factors for Hypervascularization in Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement: A Systematic Review and Meta-analysis. Acad Radiol 2020:S1076-6332(20)30512-2. [PMID: 32962925 DOI: 10.1016/j.acra.2020.08.031] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]